H
eart failure (HF) is a complex disease with a rising prevalence globally. 1 Although HF may have various primary causes, HF secondary to hypertension remains a major clinical challenge in which the disease process likely starts long before the patients become symptomatic. 1, 2 This progression of HF and its underlying molecular mechanisms remain poorly understood, despite advances in treatment to control risk factors such as hypertension. 1 Protein phosphatase 1 (PP1) is one of the most abundant and ubiquitous serine/threonine phosphatases and has long been implicated in a number of cardiac diseases, including HF. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Whereas a number of studies suggest that increased PP1 activity contributes to HF development and that its global inhibition may be therapeutic, [4] [5] [6] [7] [8] other studies provided conflicting results, [9] [10] [11] [12] as recently reviewed. 3, 13 Most studies to date considered PP1 as a single entity and measured or manipulated only its global level and/or activity. In reality, however, the PP1 holoenzyme is made up of a catalytic subunit (PP1c) and 1 (or sometimes 2) regulatory (R) subunits, which are part of a large set of ≈200 putative PP1c interactors. 14 Because there are only 4 PP1c isoforms, subcellular localization and target specificity are determined largely by the specific R subunits/interactors that bind to PP1c. In other words, PP1 should be studied as an integral part of an extensive and variable interactome. Only with such detailed understanding of the PP1 interactome can its contribution to HF pathogenesis be deciphered.
Here, we applied high-resolution affinity purification (AP)-mass spectrometry (MS), using specific anti-PP1c antibodies, 15 to study changes in the PP1 interactome of mice subjected to transverse aortic constriction (TAC) and subsequently progressed through different stages of HF. We established a robust and reproducible PP1 interactome in both mouse hearts and the HeLa cell line using a generalizable protocol, identified numerous novel PP1c interactors, and quantified their relative binding to PP1c. We then identified a number of key alterations in this interactome during HF progression that may serve as potential therapeutic targets. Finally, we showed that PP1 regulatory subunit 7 (Ppp1r7) is a key PP1c interactor important for cardiac function in vivo and that it may play a central role in regulating the PP1 interactome by acting as a competitive "sponge" to other interactors. Our study unveils the complexity and dynamics of the PP1 interactome, identifies both novel and key interactors relevant to HF pathogenesis, and provides mechanistic insights into the rearrangement of the PP1 interactome via Ppp1r7.
METHODS
Detailed experimental protocols, including data deposition, are provided in the online-only Data Supplement. The data, analytical methods, and study materials will be/have been made available to other researchers for purposes of reproducing the results or replicating the procedure. The MS proteomics data have been deposited in the ProteomeXchange Consortium via the PRIDE16 partner repository (identifier: PXD004643).
Study Animals
Protocols were approved by the Institutional Animal Care and Use Committee of Baylor College of Medicine. Wild-type male C57BL/6 mice between the ages of 3 and 4 months were either euthanized at baseline or subjected to TAC or sham surgery followed by serial echocardiography before euthanasia. Their ventricles were harvested and immediately flash-frozen in liquid nitrogen. For virus studies, 2-to 3-month-old α-myosin heavy chain wild-type and transgenic mice were anesthetized before retro-orbital injection of either control (shScr) or experimental (shPpp1r7) adeno-associated viruses (AAV9).
Transverse Aortic Constriction
Surgeries were performed according to previously published protocols. 16 Sham surgeries were similarly performed but without constriction of the aorta.
Transthoracic Echocardiography
Echocardiography was performed as previously described with the VisualSonics VeVo 770 Imaging System (VisualSonics,
Clinical Perspective
What Is New?
• Heart failure (HF) caused by long-standing hypertension is a progressive disease, but the underlying molecular mechanisms are not well understood.
• We developed a novel and unbiased way to comprehensively study protein phosphatase 1 (PP1) interactors in a mouse model of progressive heart failure induced by elevated afterload.
• Nine specific PP1 interactors were strongly associated with HF progression.
• Among these, PP1 regulatory subunit 7 was shown to play a central role in regulating the PP1 interactome by acting as a competitive molecular "sponge" of PP1c.
What Are the Clinical Implications?
• By developing a novel way to examine the binding partners of protein phosphatase 1 (the PP1 interactome), we were able to simultaneously interrogate multiple pathways relevant to HF pathogenesis. • The 9 key PP1 interactors identified in our study are highly associated with HF progression.
• Moreover, PP1 regulatory subunit 7 was shown to play a central role in HF progression.
• Understanding of molecular pathways associated with PP1 subunits may pave the way for early pharmacological intervention to forestall the progression of HF.
Data are expressed as mean±SEM. Differences between 2 groups were evaluated by an unpaired 2-tailed Student t test, whereas differences among >2 groups were evaluated by ANOVA followed by pairwise comparison tests. Adjusted p values to correct for multiple comparisons were computed with the Sidak method. The α level was set at 0.05.
RESULTS

Establishing the PP1 Interactome in the Mouse Heart
To investigate the rearrangement of the PP1 interactome during HF progression, we first set out to establish a robust and reproducible PP1 interactome. Cardiac ventricles from 8 mice were pooled into 4 samples of 2 mice each. Each of the 4 pooled samples was subjected to parallel AP with either highly selective anti-PP1c antibodies or nonspecific immunoglobulin G antibodies as control. All immunoprecipitated proteins were qualitatively and quantitatively identified with liquid chromatography-MS ( Figure 1A ). After stringent filtering, we identified 267 proteins, of which 71 were significantly enriched in the PP1c immunoprecipitation (Figure 1B and 1C and Table  I in the online-only Data Supplement). To gain insight into the abundance of each protein in the pull-down, we quantified each protein using the well-established intensity-based absolute quantification method. 18 The bait PP1c (Ppp1ca) had the highest abundance in the pull-down, demonstrating the selectivity of the antibodies. At least 10 well-known PP1c interactors, namely the various R subunits, were also significantly enriched, demonstrating the success of our immunoprecipitation. Only 1 known R subunit, Ppp1r13b, fell below the stringent statistical cutoff ( Figure 1B ; false discovery rate=0.01, s0=0.1), likely because it was detected at very low levels (Table I in the online-only Data Supplement). Although these conservative cutoff criteria minimized false positives at the expense of missing occasional true positives (only 1 that we know of), they result in a robust and reproducible PP1 interactome, against which we can confidently benchmark further studies.
Because AP-MS identifies protein complexes in addition to primary interactors, we cross-referenced every protein in our newly defined PP1 interactome with the CCSB Human Interactome Database (http://interactome.dfci.harvard.edu/H_sapiens/), which is based on yeast 2-hybrid studies mapping binary interactions ( Figure 1D ). Of the 71 proteins in the PP1 interactome, 22 proteins had at least 1 known binary interaction, clustering into at least 5 protein complexes ( Figure 1E ). The remaining 49 interactors were not cataloged and may represent novel and possible cardiac-specific interactors.
To further validate the level of enrichment achieved with the PP1c immunoprecipitation, we performed MS analysis on 2 of the same wild-type lysates without immunoprecipitation. This resulted in 1804 quantifiable proteins that were ranked according to their abundance in the mouse heart based on intensity-based absolute quantification ( Figure IA in the online-only Data Supplement). For comparison, the same analysis was performed for the 71 enriched proteins from the PP1c AP-MS data ( Figure IB in the online-only Data Supplement). Forty-four of the 71 proteins were detected in the global proteome (Table II in the online-only Data Supplement). Among the 21 that were not detected were Ppp1r2, Ppp1r11, Ppp1r8, Ppp1r18, Ppp1r12c, Ppp1r9b, Ppp1r12a, and Ppp1r13l ( Figure I in the online-only Data Supplement). This suggests that these proteins are low in abundance in the mouse heart and were detectable in our analysis only after enrichment with PP1c. Some of the other known PP1 subunits such as Ppp1r12b, Ppp1r7, and the catalytic PP1 subunits were already detected in the "full" proteome but were more highly enriched with AP-MS ( Figure I in the online-only Data Supplement). Ppp1r14c was detected only in the global proteome analysis, not in the PP1c immunoprecipitation, possibly because it has been reported to require phosphorylation by protein kinase A to bind PP1c. 19 This analysis demonstrates and confirms the success of the enrichment achieved from the AP-MS experiments.
Mouse Model of HF Progression
Once we established a robust workflow to quantify the PP1 interactome, we applied it to study a well-characterized mouse model of HF progression, the TAC model. Mouse hearts were harvested at 2, 4, 6, and 8 weeks after either TAC or sham operation ( Figure IIA in the online-only Data Supplement). The mice were grouped on the basis of their ejection fraction (EF) determined by echocardiography. The sham group consisted of mice that underwent a mock surgery and were harvested 2, 4, 6, or 8 weeks after surgery to avoid potential confounding of time since surgery (6 mice per time point for a total of 24 mice; Table III in the online-only Data Supplement). The hypertrophy, moderate HF, and severe HF groups consisted of 10 mice each with normal EF, EF between 30% and 40%, and EF <30% after TAC, respectively. One mouse with an EF of 32% had echocardiographic and physiological parameters consistent ORIGINAL RESEARCH ARTICLE with severe HF and was grouped accordingly (Table III in the online-only Data Supplement). As the animals developed HF based on final EF, their heart weight and lung weight (normalized to tibia length) increased significantly ( Figure IIB -IID in the online-only Data Supplement). Other echocardiographic parameters and physical characteristics of the animals are summarized in Table III in the online-only Data Supplement.
Proteins Associated With HF Progression
After collection of the mouse ventricles, samples were processed in parallel for PP1c AP-MS with the established workflow (Figure 2A ), which resulted in 692 identified and quantified proteins (Table IV in the online-only Data Supplement). Of these, we first sought to identify key proteins associated with HF progression, regardless of whether they were part of the PP1 interactome. A model using partial least squares (PLS) regression was built from the label-free quantification intensities of all 692 proteins to predict the final EF for a given mouse by taking into account the abundance of the proteins quantified by AP-MS. Individual proteins were assigned weights that described the covariance between their abundance and the target variable (EF) and whether this relationship was positive or negative (Table V in the online-only Data Supplement). A protein with a higher weight is more strongly associated with changes in EF. Using this model, we were able to recapitulate the grouping of all 54 mice according to their earlier classifications ( Figure 2B ). The hypertrophy group clustered with the sham group, whereas the moderate HF and severe HF groups clustered away from the sham group, with the severe HF group being the farthest away. All but 2 samples (1 sham, 1 hypertrophy) clustered within the 95% confidence interval for their respective group. This demonstrated that there were distinct differences in the AP-MS proteome during different stages of HF and that the proteomic data generated may be useful in predicting EF.
Of all the proteins used in the initial model, we were particularly interested in those that were most highly correlated with, or most predictive of, the final EF. Using a forward selection approach, we progressively added proteins in order of their PLS regression model weights. Improvement of the model was assessed by r 2 , and proteins were added until the inflection point was reached where the performance of the model plateaued ( Figure  III in the online-only Data Supplement). We defined a cutoff at this inflection point, giving us a total of 40 proteins that were the top predictors of final EF in our model (Table V in the online-only Data Supplement). Using these proteins, we repeated the PLS regression clustering and obtained a similar separation of the groups ( Figure 2C ). Clustering was slightly poorer with 4 samples outside their respective 95% confidence interval.
However, we could still accurately predict the final EF in our experimental samples by using this limited set of 40 proteins (r 2 =0.9, P<0.01). These proteins may represent key pathways or networks involved in the disease process ( Table 5 in the online-only Data Supplement).
Rearrangement of the PP1 Interactome During HF Progression
Of the 40 proteins most strongly associated with HF progression, 9 were part of the 71 PP1c interactors defined earlier, 2 of which are also known PP1 R subunits: Ppp1r7 and Ppp1r18 ( Figure 3A) . Figure 3B shows the overlap between the global proteome (1804 proteins; Figure IA in the online-only Data Supplement), PP1 interactome (71 proteins; Figure IB in the onlineonly Data Supplement), and proteins associated with HF progression (40 proteins). Although each of these data sets is informative by itself, the overlap is of particular interest because these proteins were readily detectable in our system globally, enriched with PP1c immunoprecipitation, and associated with HF progression. They include the following 7 proteins in descending order of their abundance in the proteome: Ppp1r7, Des, Dbt, Prrc1, Hnrnpm, Hsd17b8, and Bckdha (Figure 3B) . The other 2 proteins, Ppp1r18 and Ccdc85c, were not detected in the proteome but were enriched in the PP1 interactome and were associated with HF progression, so they may also be of interest for future studies. The levels of binding between these 9 proteins and PP1c during HF progression are plotted in Figure 3C in descending order of their abundance in the PP1 interactome.
Among the 9 interactors associated with HF progression, 5 had an increase in binding whereas 4 had a decrease in binding to PP1c during HF progression ( Figure 3C ). To assess whether these changes in binding to PP1c were secondary to global changes in their protein levels, we repeated the MS analysis with some of the same lysates but without PP1c immunoprecipitation ( Figure IV in the online-only Data Supplement). In total, we quantified 1931 proteins, of which 553 were significantly changed during HF progression (Table VI in the online-only Data Supplement). Of these, 14 are among the 71 PP1c interactors and 32 were among the 40 key proteins associated with HF progression on the basis of the PLS regression analysis (Table VI in the online-only Data Supplement). Five proteins, all PP1c interactors, were both significantly changed at the proteome level, and among the key proteins identified by PLS regression: Ppp1r7, Dbt, Prrc1, Hsd17b8, and Bckdha. Table VII in the online-only Data Supplement summarizes the relative changes of these interactors in terms of their levels of binding to PP1c, their global protein abundance, and their global protein level relative to the global level of PP1c in the severe HF group compared with the sham group. Among this group of select proteins, the global changes relative to PP1c were consistent with the changes in binding to PP1c for 4 of the proteins: Dbt, Prrc1, Bckdha, and Hsd17b8. This suggests that the changes in their binding to PP1c during HF progression may be partially explained by changes in their global protein expression (relative to that of PP1c). However, for Ppp1r7, there was no change in its global level relative to that of PP1c during HF progression, yet its binding to PP1c was increased. This implies that another mechanism may be responsible for the increase in binding (Table  VII in 
The Role of Ppp1r7 During HF Progression
To validate this finding for Ppp1r7 and to further investigate its role in HF progression, we performed Western blots on lysates from the 4 groups of mice (Figure 4) . The protein levels of both Ppp1r7 and PP1c increased with HF progression when normalized to calsequestrin or total protein input (Figure 4 ). However, when the level of Ppp1r7 was normalized to that of PP1c, there was no significant change in its level during HF progression ( Figure 4C ). This validates the MS findings that even though the level of Ppp1r7 bound to PP1c increased with HF progres- A, Heart tissues from mice in the 4 groups were processed in parallel. LC-MS/MS indicates liquid chromatography-tandem mass spectrometry; LFQ, label-free quantification; and XIC, extracted ion chromatogram. B, Quantified proteins from the protein phosphatase 1 catalytic subunit (PP1c) affinity purification-MS (692 proteins) were used to build a predictive model using partial least squares (PLS) regression to predict the ejection fraction of each animal. Individual dots represent individual samples, and dotted lines show the 95% confidence interval for sample group placement. Sham (black) and hypertrophy (Hyp; gray) samples group together, and severe HF (sHF; purple) clusters farthest from these groups, with overlap with moderate HF (mHF; red). C, Repeat PLS regression model using a subset of 40 proteins that were the top predictors of HF progression, identified with forward selection (see Figure III and Figure 3C ), the relative abundance of Ppp1r7 to PP1c was unchanged (Table VII in the online-only Data Supplement).
To determine whether the increased interaction between PP1c and Ppp1r7 in HF was pathogenic or compensatory, we generated a mouse model with cardiacspecific knockdown of Ppp1r7 using shRNA targeting Ppp1r7 (shPpp1r7) versus a scramble shRNA (shScr), delivered via AAV9 ( Figure VA and VB in the online-only Data Supplement). Cardiac-specific knockdown was achieved with the use of AAV9 vectors containing a loxP-flanked transcriptional stop cassette that prevents expression of the shRNA sequence in the absence of Cre recombinase. Either shPpp1r7-AAV9 or shScr-AAV9 was injected into mice expressing a constitutively active, cardiac-specific Cre (α-myosin heavy chain transgenic mice). For both vi- 
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ruses, overall transduction efficiency in ventricular myocytes was ≈70% ( Figure VC Figure VE and VF in the online-only Data Supplement). Ventricular function of these mice was evaluated with echocardiography at baseline and at 2, 4, 6, and 8 weeks after AAV9 injection, demonstrating a gradual decline in EF that is modest but significant at 6 and 8 weeks. Moreover, a corresponding increase in end-systolic diameter was significant at 8 weeks when shPpp1r7 mice were compared with shScr mice ( Figure 5 ). As an additional control, wild-type mice were also injected with shScr-AAV9, but there was no significant difference compared with transgenic mice injected with shScr-AAV9. These and other echocardiography parameters are shown in Table VIII in the online-only Data Supplement. Thus, lowering expression of Ppp1r7 led to the development of cardiac dysfunction.
To further characterize the functional effects of Ppp1r7 knockdown at the level of individual cardiomyocytes, ventricular myocytes were isolated from these mice for calcium imaging. Figure 6 shows that compared with cells isolated from shScr mice, shPpp1r7 cells had an increase in Ca sparks frequency ( Table IX in the online-only Data Supplement. Together, these data reveal that Ppp1r7 plays an essential role in cardiac function and suggest that its increased binding to PP1c during HF progression may be compensatory rather than pathogenic.
Remodeling of the PP1 Interactome Induced by PPP1R7 Knockdown
To determine the mechanism by which Ppp1r7 affects the PP1 interactome, we first noted that Ppp1r7 was the most highly bound PP1c interactor, by orders of magnitude, and therefore likely occupying the majority of PP1c molecules in the cytoplasm ( Figure IB in the online-only Data Supplement). We therefore hypothesized that Ppp1r7 may be an integral adaptor protein necessary for the binding of other interactors, a molecular "sponge" that competitively sequesters available PP1c, or both. To test this, we first established the PP1 interactome in HeLa cells, which also express PP1c and PPP1R7 at high levels ( Figure VIA in the online-only Data Supplement). 20 From this, we quantified 155 proteins, 98 of which were significantly enriched in the PP1c versus immunoglobulin G immunoprecipitation, including many known PP1 R subunits (red in Figure VIB and Table X in ORIGINAL RESEARCH ARTICLE hearts was that PPP1R8 was the most abundant interactor, with PPP1R7 being second ( Figure 1C and Figure  VIC in the online-only Data Supplement). Moreover, as a result of the better-controlled conditions in cell culture, we were able to recover more putative interactors in HeLa cells than from the mouse hearts. Because HeLa cells are widely used, the characterization of its PP1 interactome will be useful to future studies. Like before, we cross-referenced every protein in the newly defined HeLa PP1 interactome with the CCSB Human Interactome Database (http://interactome. dfci.harvard.edu/H_sapiens/; Figure VID Once we established a robust PP1 interactome in HeLa cells, we knocked down PPP1R7 using siRNA before performing AP-MS experiments to investigate its effect on the PP1 interactome ( Figure 7A ). Western blot shows that PPP1R7 was knocked down ≈70% without affecting global PP1c levels (P<0.001; Figure 7B and 7C) . Figure 7D plots the relative changes in the interactors from the PP1c AP-MS with PPP1R7 knockdown (Table XI in the online-only Data Supplement). This analysis showed that there was a general increase in almost all of the other interactors, supporting the hypothesis that PPP1R7 serves as a competitive molecular sponge. On the other hand, a few proteins had a decreased level, most notably UXT, YBX3 (also known as CSDA), and TPRN, all of which may depend on PPP1R7 for indirect binding to PP1c. Finally, proteins that were in the same complexes on the basis of yeast 2-hybrid analyses ( Figure VID and VIE in the online-only Data Supplement) all changed in the same direction as expected (same symbols in Figure 7D ). These findings support the notion that PPP1R7 regulates the PP1 interactome globally by competitively sequestering PP1c molecules.
DISCUSSION
In this study, we established a robust and reproducible PP1 interactome using AP-MS and identified 71 and 98 putative PP1c interactors from mouse cardiac tissues and HeLa cells, respectively, most of which have not been previously reported (Figures 1 and 7 and Tables I and X in the online-only Data Supplement). Next, using the well-established TAC mouse model, we showed that the PP1 interactome becomes rearranged in HF. Our studies identified 40 key proteins that are strongly associated with HF progression, 9 of which are PP1c 
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interactors (Figures 2 and 3 and Tables IV through VI in the online-only Data Supplement). Of these, Ppp1r7 has the highest binding to PP1c in mouse ventricles, and its knockdown in vivo led to the development of cardiac dysfunction in adult mice and increased Ca sparks in isolated ventricular myocytes (Figures 5 and 6) . Using HeLa cells, we showed that Ppp1r7 regulates the PP1 interactome by acting as a competitive "sponge" of PP1c ( Figure 7 and Table XI in the online-only Data Supplement). Together, the results from our study suggest that Ppp1r7 plays an essential role in cardiac function by regulating the PP1 interactome, which becomes rearranged during HF progression.
New Approaches in Studying PP1
Dysregulation of protein phosphorylation is an important mechanism that underlies numerous diseases, including atrial fibrillation (AF) and HF. 3, [21] [22] [23] Whereas a number of studies have investigated the pathogenic role of protein kinases and developed pharmacological interventions, relatively few studies have done the same for protein phosphatases. 3 The reason may be that protein kinases are widely diverse and thereby specific in their subcellular localization and substrate selection, making them ideal targets for pharmacological interventions. In contrast, protein phosphatases are highly homologous in their catalytic subunits and instead depend on their R subunits or interactors to achieve the same functional specificity.
14 Although this extra layer of complexity creates additional challenges to their study, it holds the key to unexplored opportunities for novel drug design. This concept was nicely demonstrated by a recent study in which a small molecule, guanabenz, selectively disrupted the interaction between PP1c and PPP1R15A (also known as GADD34), thereby preventing the stress-induced dephosphorylation of the α subunit of translation initiation factor 2 by PP1, and rescuing the cells from protein misfolding stress. 24 In terms of cardiovascular diseases such as HF, significant controversy exists surrounding the exact role(s) of PP1, as recently reviewed. 3, 13 The reason may be that most previous studies considered PP1 a single enzyme without adequately addressing its interactome. With this in mind, we previously undertook a large-scale unbiased study to map changes in the PP1 interactome in AF 15 ; that study became the basis of the present study. However, the major limitation of that study was that a single AP-MS run was used to map the PP1 interactome in mouse ventricles and another one in human atria. 15 The present study was designed to provide a more robust and reproducible PP1 interactome, against which future studies may be benchmarked. To this end, we used 4 biological replicates and stringent statistical cutoffs to map the PP1 interactomes for both mouse ventricles and HeLa cells ( Figure 1A through 1C and Figure VIA through VIC in the online-only Data Supplement). Furthermore, we cross-referenced each putative interactor against all others in the CCSB Human Interactome Database to identify interactors that belong to the same protein complexes ( Figure 1D and 1E and Figure  VID and VIE in the online-only Data Supplement). The limited numbers of complexes identified (5 and 8 for mouse ventricles and HeLa cells, respectively) may be the result of the fact that large-scale yeast 2-hybrid screens have relatively low sensitivity, that most of the interactors identified in our AP-MS are secondary/tertiary interactors, or both. In addition, a limitation inherent of AP-MS is that these interactions were captured in homogenates and thus may not completely recapitulate the interactome in vivo, although specific care was taken to preserve native conditions. In any case, we believe that this novel approach and the high-quality data sets produced in this study will be invaluable not only to the cardiovascular field but also to the scientific community in general. 
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Novel Findings and Potential Clinical Implications
Besides generating a number of rich data sets, the present study produced a number of significant findings in understanding HF progression. First, we identified a set of 40 proteins with bindings to PP1c that are strongly associated with HF progression (Table V in the online-only Data Supplement and Figure 2B and 2C). In fact, the binding of these proteins to PP1c changed consistently during HF progression and may be used to predict the EF of the animal. Although they may be impractical as clinical biomarkers because their levels were measured after PP1c immunoprecipitation, they may represent key proteins, pathways, or networks that are involved in disease progression. Among this group of 40, 9 are of particular interest because they are either known (Ppp1r7 and Ppp1r18) or putative (Des, Dbt, Prrc1, Ccdc85c, Hnrnpm, Hsd17b8, and Bckdha) interactors based on our newly defined PP1 interactome ( Figure 3 ). To understand why the binding of these proteins to PP1c either increased or decreased during HF progression, we compared the level of their binding first to their global changes and then to their global changes relative to the global changes of PP1c during HF progression (Table VII in the online-only Data Supplement). For 4 of the proteins (Dbt, Prrc1, Bckdha, and Hsd17b8), the changes in their binding to PP1c corresponded to their global changes relative to PP1c. In other words, their increase or decrease in PP1c binding is at least partially explained by their global increase or decrease. However, this was not the case for Ppp1r7, for which there was no relative global increase (compared with PP1c, which was also increased globally). In other words, the increase in the binding of Ppp1r7 to PP1c cannot be accounted for by its global expression changes. This was the same finding in patients with paroxysmal AF in that PPP1R7 was also increased in its binding to PP1c without significant global increase relative to PP1c. 15 To explore the role of Ppp1r7 in vivo, we knocked down Ppp1r7 in mouse cardiomyocytes, which resulted in cardiac dysfunction in mice and increased Ca sparks in isolated ventricular myocytes, although the total knockdown level was modest (≈25%; Figures 5 and 6 ). Because Ca sparks are directly related to sarcoplasmic reticulum Ca release via the ryanodine receptor type 2, increased Ca sparks frequency normalized to sarcoplasmic reticulum Ca load implies ryanodine receptor type 2 hyperactivity, a mechanism that has previously been shown to underlie several cardiac diseases, including HF. 22 This implies that Ppp1r7 knockdown may either directly or indirectly lead to ryanodine receptor type 2 hyperactivity and HF in our model and that its increased interaction with PP1c found during HF progression may be compensatory rather than pathogenic.
Because Ppp1r7 is the top interactor of PP1c by a considerable amount in mouse ventricles ( Figure IB in the online-only Data Supplement), we theorized that it may act as either a necessary adaptor protein for other interactors or a competitive sponge that sequesters available PP1c. When we knocked down PPP1R7 in HeLa cells, the majority of putative PP1c interactors were increased in their binding to PP1c, suggesting a competitive process with PPP1R7 ( Figure 7) . Therefore, the increase in binding between Ppp1r7 and PP1c during HF progression (Figure 3 ) (and in AF 15 ) may lead to a decrease in binding of many other interactors and thereby affect phosphorylation of downstream targets. This makes Ppp1r7 an attractive therapeutic target, although future studies are needed to further characterize its role(s) in HF progression.
On the other hand, PPP1R7 may also act as an adaptor protein for some of the interactors because a few of those had a decrease in their PP1c binding with PPP1R7 knockdown (Figure 7) . The binding between PP1c and YBX3 (aka CSDA) was decreased (although nonsignificantly), suggesting that CSDA may bind to PP1c secondarily through PPP1R7 ( Figure 7D ). If this is the case, our previous finding of the increase in PP1c-CSDA binding in paroxysmal AF may actually be secondary to the increase in the PP1c-PPP1R7 binding in which CSDA was not a primary interactor as suggested. 15 In any case, further work is needed to clarify this interaction, which may have potential implications in disease.
Conclusions
By applying state-of-the-art AP-MS methods, we have established the most complete PP1 interactome to date in both mouse hearts and HeLa cells. Our studies identified key PP1c interactors that were altered in their binding to PP1c during HF progression. In particular, we showed that Ppp1r7 may play a central role during cardiac remodeling by acting as a competitive sponge of PP1c. This study contributes multiple rich data sets and mechanistic insights into our understanding of the rearrangement of PP1 interactome during HF progression.
